Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 2
2021 6
2022 10
2023 9
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Biomarkers for immunotherapy response in head and neck cancer.
Gavrielatou N, Doumas S, Economopoulou P, Foukas PG, Psyrri A. Gavrielatou N, et al. Cancer Treat Rev. 2020 Mar;84:101977. doi: 10.1016/j.ctrv.2020.101977. Epub 2020 Jan 24. Cancer Treat Rev. 2020. PMID: 32018128 Review.
Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.
Moutafi MK, Molero M, Martinez Morilla S, Baena J, Vathiotis IA, Gavrielatou N, Castro-Labrador L, de Garibay GR, Adradas V, Orive D, Valencia K, Calvo A, Montuenga LM, Ponce Aix S, Schalper KA, Herbst RS, Paz-Ares L, Rimm DL, Zugazagoitia J. Moutafi MK, et al. Among authors: gavrielatou n. J Immunother Cancer. 2022 Aug;10(8):e004757. doi: 10.1136/jitc-2022-004757. J Immunother Cancer. 2022. PMID: 36002182 Free PMC article.
Immune checkpoint inhibitors in sarcomas: a systematic review.
Anastasiou M, Kyriazoglou A, Kotsantis I, Economopoulou P, Kyrkasiadou M, Giannopoulou A, Kosmidou A, Smerdi D, Moutafi M, Gavrielatou N, Psyrri A. Anastasiou M, et al. Among authors: gavrielatou n. Immunooncol Technol. 2023 Sep 28;20:100407. doi: 10.1016/j.iotech.2023.100407. eCollection 2023 Dec. Immunooncol Technol. 2023. PMID: 38192615 Free PMC article. Review.
Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer.
Moutafi M, Koliou GA, Papaxoinis G, Economopoulou P, Kotsantis I, Gkotzamanidou M, Anastasiou M, Pectasides D, Kyrodimos E, Delides A, Giotakis E, Papadimitriou NG, Panayiotides IG, Perisanidis C, Fernandez AI, Xirou V, Poulios C, Gagari E, Yaghoobi V, Gavrielatou N, Shafi S, Aung TN, Kougioumtzopoulou A, Kouloulias V, Palialexis K, Gkolfinopoulos S, Strati A, Lianidou E, Fountzilas G, Rimm DL, Foukas PG, Psyrri A. Moutafi M, et al. Among authors: gavrielatou n. Cancer Res Commun. 2023 Aug 10;3(8):1514-1523. doi: 10.1158/2767-9764.CRC-23-0051. eCollection 2023 Aug. Cancer Res Commun. 2023. PMID: 37575280 Free PMC article. Clinical Trial.
B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.
Gavrielatou N, Fortis E, Spathis A, Anastasiou M, Economopoulou P, Foukas GRP, Lelegiannis IM, Rusakiewicz S, Vathiotis I, Aung TN, Tissot S, Kastrinou A, Kotsantis I, Vagia EM, Panayiotides I, Rimm DL, Coukos G, Homicsko K, Foukas P, Psyrri A. Gavrielatou N, et al. Ann Oncol. 2024 Apr;35(4):340-350. doi: 10.1016/j.annonc.2023.12.011. Epub 2023 Dec 28. Ann Oncol. 2024. PMID: 38159908 Free article. Clinical Trial.
Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms.
Kyriazoglou A, Pagkali A, Kotsantis I, Economopoulou P, Kyrkasiadou M, Moutafi M, Gavrielatou N, Anastasiou M, Boulouta A, Pantazopoulos A, Giannakakou M, Digklia A, Psyrri A. Kyriazoglou A, et al. Among authors: gavrielatou n. Cancer Treat Rev. 2024 Apr;125:102716. doi: 10.1016/j.ctrv.2024.102716. Epub 2024 Mar 11. Cancer Treat Rev. 2024. PMID: 38492514 Review.
Editorial: Immunology and Immunotherapy of Head and Neck Cancer.
Gavrielatou N, Economopoulou P, Kotsantis I, Psyrri A. Gavrielatou N, et al. Front Oncol. 2021 Dec 6;11:815763. doi: 10.3389/fonc.2021.815763. eCollection 2021. Front Oncol. 2021. PMID: 34938666 Free PMC article. No abstract available.
High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC).
Moutafi MK, Bates KM, Aung TN, Milian RG, Xirou V, Vathiotis IA, Gavrielatou N, Angelakis A, Schalper KA, Salichos L, Rimm DL. Moutafi MK, et al. Among authors: gavrielatou n. J Immunother Cancer. 2024 Jun 10;12(6):e009039. doi: 10.1136/jitc-2024-009039. J Immunother Cancer. 2024. PMID: 38857914 Free PMC article.
Development of an immunohistochemical assay for Siglec-15.
Shafi S, Aung TN, Robbins C, Zugazagoitia J, Vathiotis I, Gavrielatou N, Yaghoobi V, Fernandez A, Niu S, Liu LN, Cusumano ZT, Leelatian N, Cole K, Wang H, Homer R, Herbst RS, Langermann S, Rimm DL. Shafi S, et al. Among authors: gavrielatou n. Lab Invest. 2022 Jul;102(7):771-778. doi: 10.1038/s41374-022-00785-9. Epub 2022 Apr 22. Lab Invest. 2022. PMID: 35459795 Free PMC article.
32 results